Benefits
ADHD adolescents with mGluR mutations
A 5-week open-label single-blind placebo-controlled study in 30 adolescents (12–17 years) with ADHD harboring mutations in mGluR network genes showed significant improvement in CGI-Improvement and CGI-Severity (3.79→2.33 for CGI-I, 4.83→3.86 for CGI-S, both P<0.001). Treatment was effective from 50–800 mg, with most gains at 400 mg BID. Genetic-targeted approach: mGluR network mutations represent ~10% of ADHD cases. Limited by open-label design and small sample.
Vascular dementia (failed Phase 3)
Nippon Shinyaku conducted Phase 3 clinical trials for vascular dementia in Japan in early 1990s. Results: abandoned due to lack OF efficacy. Important negative evidence — substantial Japanese pharmaceutical investment concluded efficacy insufficient for approval. Honest framing: failed Phase 3 vascular dementia trial is significant counter-evidence to nootropic claims.
mGluR (metabotropic glutamate receptor) modulation
Fasoracetam is a metabotropic glutamate receptor (mGluR) activator — specifically affecting mGluR network. Mechanism distinct from other racetams (AMPA modulators, HACU enhancers). Theoretical basis for genetic-targeted ADHD approach (Hakonarson) and possible utility in DiGeorge syndrome and other glutamatergic disorders. Phase 2 DiGeorge syndrome trial ongoing (NB-001).
DiGeorge syndrome adjunct (Phase 2 ongoing, Nobias)
Nobias Therapeutics developing fasoracetam (NB-001) for DiGeorge syndrome (22q11.2 deletion syndrome) — Phase 2 trials as of October 2023. DiGeorge syndrome involves mGluR gene region deletion; fasoracetam's mechanism theoretically compensates. Active development pipeline despite Avalo Therapeutics' abandonment of ADHD/autism/depression indications. Results pending.
FDA Orphan Drug Designation (significant)
Fasoracetam received FDA orphan drug designation (date varies by indication). Designation enables certain regulatory benefits but is not FDA approval. Recognition reflects unmet medical need in target conditions but does not establish efficacy. Historically meaningful regulatory milestone in development trajectory.
Mechanism of action
Metabotropic glutamate receptor (mGluR) activation
Fasoracetam acts as metabotropic glutamate receptor activator — affects mGluR network signaling. Distinguishing mechanism from AMPA-modulating racetams (aniracetam) and HACU-enhancing racetams (pramiracetam, coluracetam). Theoretical basis for ADHD therapeutic approach in patients with mGluR pathway dysfunction.
Cholinergic pathway effects
Some evidence for cholinergic effects beyond glutamatergic mechanism. May activate NMDA receptors compensating for cholinergic dysfunction in certain contexts. Mechanism relevant to broader cognitive enhancement claims.
GABA-B receptor modulation
Animal studies suggest fasoracetam upregulates GABA-B receptors after chronic dosing. Mechanism for proposed mood-stabilizing or anxiolytic effects. Less clinically validated than glutamatergic effects.
BBB penetration via lipophilicity
Crosses BBB readily. CNS effects achievable at typical oral doses (400-800 mg). Pharmacokinetics generally favorable for oral administration.
Clinical trials
Phase 1 open-label single-blind placebo-controlled study (Hakonarson H, Elia J, et al. 2017, Mol Psychiatry doi:10.1038/mp.2017.221). Aevi Genomic Medicine sponsor.
30 adolescents (12-17 years) with ADHD harboring mutations in mGluR network genes. 5-week protocol: 50-800 mg single-dose PK, 1 week single-blind placebo, then symptom-driven dose escalation up to 400 mg BID for 4 weeks. Mutation status double-blinded; subjects single-blinded (aware of dose escalation).
NFC-1 (fasoracetam) treatment significantly improved ADHD symptoms in genetically-selected subgroup. CGI-Improvement: 3.79 baseline → 2.33 week 5 (P<0.001). CGI-Severity: 4.83 baseline → 3.86 week 5 (P<0.001). Effective from 50-800 mg, most gains at 400 mg BID. Foundational evidence for genetic-targeted ADHD approach. Limitations: open-label single-blind (not double-blind clinical trial), single-center (CHOP), small sample (n=30), genetic-selected population (~10% of ADHD cases).
Phase 3 clinical trials for vascular dementia conducted by Nippon Shinyaku in Japan, early 1990s.
Japanese patients with vascular dementia in Phase 3 trials. Sample sizes and specific designs not fully published in English literature.
Failed efficacy. Nippon Shinyaku abandoned development of fasoracetam for vascular dementia indication. Significant negative evidence — substantial Japanese pharmaceutical investment concluded efficacy insufficient for approval. Important historical context for fasoracetam's clinical evidence base.
Avalo Therapeutics (previously Cerecor) clinical development for multiple indications.
Trials in ADHD, autistic disorder, cognition disorders, DiGeorge syndrome, major depressive disorder.
ALL indications discontinued by 2018. AEVI-004 (co-crystallized form) under development for ADHD, autistic disorder, epilepsy — no recent development as of. Multiple-indication abandonment is significant negative evidence about commercial viability and demonstrated efficacy. Current status: Nobias Therapeutics (NB-001) developing for DiGeorge syndrome only — Phase 2 as of. Demonstrates that despite multiple development attempts, fasoracetam has not achieved approval for any indication.